Oncolytics Biotech Inc.
ONCY
Rank in Stocks
#23570
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in... Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Share Price
$0.4077
Last synced: 2026-11-09
Market Cap
$40.92M
Change (1 day)
-7.21%
Change (1 year)
-62.25%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncolytics Biotech Inc. (ONCY)
Category
Healthcare
Operating Margin for Oncolytics Biotech Inc. (ONCY)
Operating Margin as of November 2026 TTM: 0.00%
According to Oncolytics Biotech Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Oncolytics Biotech Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -756.22% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | -100.00% |
| 2005 | -1,599.39% | -11.40% |
| 2004 | -1,805.23% | -14.54% |
| 2003 | -2,112.40% | -34.65% |
| 2002 | -3,232.38% | 0.00% |
| 2001 | 0.00% | -100.00% |
| 2000 | -1,498.60% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oncolytics Biotech Inc.'s operating margin
What was Oncolytics Biotech Inc.'s operating margin in 2025?
In 2025, Oncolytics Biotech Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Oncolytics Biotech Inc.'s operating margin changed since 2020?
From 2020 to 2025, Oncolytics Biotech Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Oncolytics Biotech Inc.'s operating margin compare with similar companies?
Oncolytics Biotech Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.